FindTrial
Sign In

1 mg

DRUG6 trials

Sponsors

Lysarc, Assistance Publique Hopitaux De Paris, Hospices Civils De Lyon, Agios Pharmaceuticals Inc., Medical University Of Warsaw

Conditions

Anemia in subjects with sickle cell disease (SCD)Children primary nephropathy IgAHealthyIVF (In vitro fertilization) or ICSI (intracytoplasmic sperm injection) protocol with embryo transfer planned on the same cycle.Peripheral T-cell lymphoma (PTCL)Renal Transplantation

Phase 1

Multiple Oral Doses Of PH-797804 In Healthy Japanese Adult Subjects
CompletedNCT01217918
PfizerHealthy
Start: 2010-10-31End: 2011-02-28Updated: 2011-02-15

Phase 2

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Mitapivat in Subjects With Sickle Cell Disease.
Not yet recruitingCTIS2024-515202-84-00
Agios Pharmaceuticals Inc.Anemia in subjects with sickle cell disease (SCD)
Target: 66Updated: 2026-01-26

Phase 3

SOLOAGO - Luteal phase support by GnRH agonist alone after GnRH agonist triggering compared to the reference protocol (hCG triggering and luteal support with progesterone) in IVF: a randomized controlled trial.
RecruitingCTIS2023-505126-34-00
Assistance Publique Hopitaux De ParisIVF (In vitro fertilization) or ICSI (intracytoplasmic sperm injection) protocol with embryo transfer planned on the same cycle.
Start: 2024-06-27Target: 652Updated: 2025-05-21
SABINE - The efficacy and Safety of delayed-release Budesonide in children with primary IgA nephropathy - a multicenter, interventional phase III, randomized, placebo-controlled, double-blind study.
Not yet recruitingCTIS2024-518759-45-00
Medical University Of WarsawChildren primary nephropathy IgA
Target: 120Updated: 2025-11-25

Phase 4

TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma
RecruitingCTIS2022-501710-62-02
LysarcPeripheral T-cell lymphoma (PTCL)
Start: 2023-06-07Target: 204Updated: 2026-01-19
Efficiency of everolimus for the treatment of kidney transplanted patients presenting a missing self-induced NK-mediated rejection (STARR)
RecruitingCTIS2024-513814-37-00
Hospices Civils De LyonRenal Transplantation
Start: 2020-12-03Target: 20Updated: 2024-09-30